RSS Feed ALL

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

5 days ago

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

7 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

14 days ago

· IMAAVY is an immunoselective FcRn blocker designed to target and reduce...

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

14 days ago

· IMAAVY is an immunoselective FcRn blocker designed to target and reduce...

Johnson & Johnson Announces New Global Classification System for Surgical Outcomes

15 days ago

Peer-reviewed DISH Classification System establishes a standardized approach to reporting dehiscence, infection...

Johnson & Johnson Publishes New Future of Digital Surgery Report to Help Define the Emerging Field of Surgical Intelligence

21 days ago

Drawing on insights from leaders across healthcare, technology, policy and investment, the...

Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy

22 days ago

Introducing MONARCH™ QUEST 3, the latest software update for the MONARCH™ Platform...

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

28 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

about 1 month ago

Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

about 1 month ago

Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

about 1 month ago

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or...

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

about 1 month ago